OR
CERE

Olympiad Research’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Olympiad Research’s Portfolio CERE Stock Details CERE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-52,423
Closed -$2.14M – 500
2024
Q2 		$2.14M Buy
52,423
+5,119
+11% +$213K 1.58% 1
2024
Q1 		$2M Hold
47,304
– – 1.31% 10
2023
Q4 		$2.01M Buy
+47,304
New +$1.36M 1.58% 4

Other funds holding CERE

IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return

Olympiad Research's CERE Position: Q3 2024 in Review

Olympiad Research sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q3 2024, closing a stake of 52,423 shares — an estimated $2.14M sold.

Olympiad Research first reported a position in CERE in Q4 2023 and held it in 3 quarters. The position peaked at $2.14M in Q2 2024. 2 funds tracked by Wall St. Rank hold CERE as of Q3 2024.

  • Olympiad Research reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
  • Olympiad Research sold 52,423 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q3 2024, an estimated $2.14M.
  • Olympiad Research first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q4 2023 and held it in 3 quarters.
  • Olympiad Research's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $2.14M in Q2 2024.
  • 2 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q3 2024.

Based on Olympiad Research's 13F filing for Q3 2024, filed 31 Oct 2024.